BACKGROUND: Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly used in colorectal cancer (CRC) screening programmes. Faecal immunochemical tests (FITs) are thought to be superior. AIM: To compare performance of a g-FOBT and a quantitative FIT for detection of CRCs and advanced adenomas in a colonoscopy-controlled population. METHODS: We assessed sensitivity and specificity of both FIT (OC-sensor) and g-FOBT (Hemoccult-II) prior to patients' scheduled colonoscopies. RESULTS: Of the 62 invasive cancers detected in 1821 individuals, g-FOBT was positive in 46 and FIT in 54 (74.2% vs. 87.1%, P = 0.02). Among 194 patients with advanced adenomas, g-FOBT was positive in 35 and FIT in 69 (18.0% vs. 35.6%, P < 0.001). Sensitivity for screen relevant tumours (197 advanced adenomas and 28 stage I or II cancers) was 23.0% for g-FOBT and 40.5% for FIT (P < 0.001). Specificity of g-FOBT compared to FIT for the detection of cancer was 95.7% vs. 91.0%, P < 0.001) and for advanced adenomas (97.4% vs. 94.2%, P < 0.001). CONCLUSIONS: Faecal immunochemical test is more sensitive for CRC and advanced adenomas. Sensitivity of FIT for screen relevant tumours, early-stage cancers and advanced adenomas, is significantly higher. Specificity of g-FOBT is higher compared with FIT.
BACKGROUND: Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly used in colorectal cancer (CRC) screening programmes. Faecal immunochemical tests (FITs) are thought to be superior. AIM: To compare performance of a g-FOBT and a quantitative FIT for detection of CRCs and advanced adenomas in a colonoscopy-controlled population. METHODS: We assessed sensitivity and specificity of both FIT (OC-sensor) and g-FOBT (Hemoccult-II) prior to patients' scheduled colonoscopies. RESULTS: Of the 62 invasive cancers detected in 1821 individuals, g-FOBT was positive in 46 and FIT in 54 (74.2% vs. 87.1%, P = 0.02). Among 194 patients with advanced adenomas, g-FOBT was positive in 35 and FIT in 69 (18.0% vs. 35.6%, P < 0.001). Sensitivity for screen relevant tumours (197 advanced adenomas and 28 stage I or II cancers) was 23.0% for g-FOBT and 40.5% for FIT (P < 0.001). Specificity of g-FOBT compared to FIT for the detection of cancer was 95.7% vs. 91.0%, P < 0.001) and for advanced adenomas (97.4% vs. 94.2%, P < 0.001). CONCLUSIONS: Faecal immunochemical test is more sensitive for CRC and advanced adenomas. Sensitivity of FIT for screen relevant tumours, early-stage cancers and advanced adenomas, is significantly higher. Specificity of g-FOBT is higher compared with FIT.
Authors: Sietze T van Turenhout; Leo G M van Rossum; Frank A Oort; Robert J F Laheij; Anne F van Rijn; Jochim S Terhaar sive Droste; Paul Fockens; René W M van der Hulst; Anneke A Bouman; Jan B M J Jansen; Gerrit A Meijer; Evelien Dekker; Chris J J Mulder Journal: World J Gastroenterol Date: 2012-10-14 Impact factor: 5.742
Authors: Grace Clarke Hillyer; Karen M Schmitt; Daniel E Freedberg; Rachel A Kramer; Yin Su; Richard M Rosenberg; Alfred I Neugut Journal: Am J Prev Med Date: 2014-06-17 Impact factor: 5.043
Authors: Linda J W Bosch; Sandra Mongera; Jochim S Terhaar Sive Droste; Frank A Oort; Sietze T van Turenhout; Maarten T Penning; Joost Louwagie; Chris J J Mulder; Manon van Engeland; Beatriz Carvalho; Gerrit A Meijer Journal: Cell Oncol (Dordr) Date: 2012-07-21 Impact factor: 6.730
Authors: A T M Dilshad Chowdhury; Gaius Longcroft-Wheaton; Andrew Davis; David Massey; Patrick Goggin Journal: Frontline Gastroenterol Date: 2014-01-27
Authors: Douglas L Riegert-Johnson; Lisa A Boardman; Julia E Crook; Colleen S Thomas; Ruth A Johnson; Maegan E Roberts Journal: Int J Biol Markers Date: 2012-12-27 Impact factor: 2.659
Authors: Amit G Singal; Douglas A Corley; Aruna Kamineni; Michael Garcia; Yingye Zheng; Paul V Doria-Rose; Virginia P Quinn; Christopher D Jensen; Jessica Chubak; Jasmin Tiro; Chyke A Doubeni; Nirupa R Ghai; Celette Sugg Skinner; Karen Wernli; Ethan A Halm Journal: Am J Gastroenterol Date: 2018-02-27 Impact factor: 10.864